Mercedes Bermejo

Mercedes Bermejo

Auto-generated profile, based on publicly available information

Mercedes Bermejo

AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Journal of Molecular Biology
Verified
Journal Article
Closed access
CGCarelia García-Moruja
Carelia García-Moruja
JAJuan M. Alonso-Lobo
Juan M. Alonso-Lobo
PRPatricia Rueda
Patricia Rueda
CTCarmen Torres
Carmen Torres
NGNuria González
Nuria González
Antonio CaruzAntonio Caruz
Antonio Caruz

1 March 2016 in Cell Reports
Verified
Journal Article
Open access
MCMayte Coiras
Mayte Coiras
MBMercedes Bermejo
Mercedes Bermejo
BDBenjamin Descours
Benjamin Descours
EMElena Mateos
Elena Mateos
JGJavier García-Pérez
Javier García-Pérez
JAJosé Alcami
José Alcami
HIV-1 post-integration latency in CD4+ lymphocytes is responsible for viral persistence despite treatment, but mechanisms involved in the establishment of latent viral reservoirs are not fully understood. We determined that both interleukin 2 (IL-2) and IL-7 induced SAMHD1 phosphorylation in T592, abrogating its antiviral activity. However, IL-7 caused a much more profound stimulatory effect on HIV-1 reverse transcription and integration than IL-2 that required chemokine co-stimulation. Both cytokines barely induced transcription due to low NF-κB induction, favoring the establishment of latent reservoirs. Effect of IL-7 on SAMHD1 phosphorylation was confirmed in IL-7-treated patients (ACTG 5214 study). Dasatinib--a tyrosine-kinase inhibitor--blocked SAMHD1 phosphorylation induced by IL-2 and IL-7 and restored HIV-1 restriction. We propose that γc-cytokines play a major role in the reservoir establishment not only by driving homeostatic proliferation but also by increasing susceptibility of CD4+ lymphocytes to HIV-1 infection through SAMHD1 inactivation.

1 February 1997 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
JBJosé M. Benito
José M. Benito
JZJosé M. Zabay
José M. Zabay
JGJuana Gil
Juana Gil
MBMercedes Bermejo
Mercedes Bermejo
AEAsunción Escudero
Asunción Escudero
EFEduardo Fernández-Cruz
Eduardo Fernández-Cruz
We determined the representation in asymptomatic human immunodeficiency virus (HIV) infection of the CD45RO+ and CD45RO − CD45RA+ subsets of CD4+ and CD8+ T lymphocytes, CD11b+ and CD11b− subsets of CD8+ T cells, and activated populations of these subsets. Three-color flow cytometry was used to quantitate the different CD4+ and CD8+ T cell populations in 116 asymptomatic HIV+ individuals. In asymptomatic HIV+ infection there was a significant relative increase in the CD4+ CD45RO+ and CD8+ CD45RO+ T cell subsets, which express CD38 and DR antigens, that correlated strongly with the decline in total CD4+ T cells. In addition, we found a loss of CD4+ CD45RO− and CD8+ CD45RO− T cells associated with progression of HIV infection (as measured by the decline in total CD4+ T cells). Studies presented here also indicate that, with the progression of asymptomatic HIV infection. CD8+ CD11b− T lymphocytes showed a significant decreases, whereas CD8+ CD11b+ T cells were significantly increased. This study demonstrates that the progression of HIV infection in asymptomatic patients involves the increase in CD45RO+ subsets of CD4+ and CD8+ T cells, the increase in CD8+ CD11b+ T cells, the decrease in CD45RO − CD45RA+ subsets of CD4 and CD8 T cells, and the decline in CD8+ CD11b− T cells.

1 April 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MBMercedes Bermejo
Mercedes Bermejo
MHMaría Rosa López Huertas
María Rosa López Huertas
JGJavier García-Pérez
Javier García-Pérez
Núria ClimentNúria Climent
Núria Climent
BDBenjamin Descours
Benjamin Descours
MCMayte Coiras
Mayte Coiras

1 May 2004 in Antiviral Therapy
Verified
Journal Article
Closed access
JRJoaquín Rullas
Joaquín Rullas
MBMercedes Bermejo
Mercedes Bermejo
JGJavier García-Pérez
Javier García-Pérez
MBManuela Beltrán
Manuela Beltrán
NGNuria González
Nuria González
JAJosé Alcami
José Alcami
Induction of HIV expression through lymphocyte activation has been proposed as a strategy to purge latent reservoirs. Prostratin is a non-tumourogenic phorbol ester that delays HIV replication in vitro, but paradoxically activates HIV expression in latently infected cells. To get a better insight into the mechanisms of action of prostratin, we have analysed the effect of prostratin on HIV activation and HIV receptor and coreceptors’ surface expression in human lymphocytes. Peripheral blood mononuclear cells (PBMCs) were transfected with luciferase expression constructs under the control of wild type HIV-long terminal repeat (LTR) and consensus sequences for transcription factors involved in HIV-LTR transactivation (NF-κB, SP1, NFAT). Prostratin stimulates transactivation of LTR vectors, κB- and SP-1-driven luciferase constructs. In another set of experiments, PBMCs were transfected with a full-length infectious viral clone. Prostratin induced HIV transcription and viral expression as detected by luciferase activity in cellular extracts and p24 levels in culture supernatants, respectively. Expression of the HIV coreceptors CCR5 and CXCR4 was decreased by prostratin and, concomitantly, prostratin inhibited the infection of PBMCs with R5 and X4 strains. However, prostratin did not inhibit infection with a pseudotyped viral clone that enters into the cells independently of HIV receptors. These results help to explain the paradoxical effects of prostratin. On one hand, prostratin induces HIV activation in latently infected cells through the induction of NF-κB and Sp1. On the other hand, strong and persistent downregulation of HIV receptors decreases infection of new targets and delays HIV propagation. These data support the potential use of prostratin to activate HIV from latency and purge viral reservoirs.

2 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMaría Sánchez-Del Cojo
María Sánchez-Del Cojo
MHMaría Rosa López Huertas
María Rosa López Huertas
FDFrancisco Diez-Fuertes
Francisco Diez-Fuertes
SRSara Rodríguez-Mora
Sara Rodríguez-Mora
MBMercedes Bermejo
Mercedes Bermejo
MCMayte Coiras
Mayte Coiras
HIV-1 induces changes in the miRNA expression profile of infected CD4+ T cells that could improve viral replication. HIV-1 regulator Tat modifies the cellular gene expression and has been appointed as an RNA silencing suppressor. Tat is a 101-residue protein codified by two exons that regulates the elongation of viral transcripts. The first exon of Tat (amino acids 1–72) forms the transcriptionally active protein Tat72, but the presence of the second exon (amino acids 73–101) results in a more competent regulatory protein (Tat101) with additional functions. Intracellular, full-length Tat101 induces functional and morphological changes in CD4+ T cells that contribute to HIV-1 pathogenesis such as delay in T-cell proliferation and protection against FasL-mediated apoptosis. But the precise mechanism by which Tat produces these changes remains unknown. We analyzed how the stable expression of intracellular Tat101 and Tat72 modified the miRNA expression profile in Jurkat cells and if this correlated with changes in apoptotic pathways and cell cycle observed in Tat-expressing cells. Specifically, the enhanced expression of hsa-miR-21 and hsa-miR-222 in Jurkat-Tat101 cells was associated with the reduced expression of target mRNAs encoding proteins related to apoptosis and cell cycle such as PTEN, PDCD4 and CDKN1B. We developed Jurkat cells with stable expression of hsa-miR-21 or hsa-miR-222 and observed a similar pattern to Jurkat-Tat101 in resistance to FasL-mediated apoptosis, cell cycle arrest in G2/M and altered cell morphology. Consequently, upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells.